Lansoprazole

From Wikipedia, the free encyclopedia

Lansoprazole
Systematic (IUPAC) name
2-[(3-methyl-4-(2,2,2-trifluoroethoxy) pyridin-2-yl) methylsulfinyl] -1H-benzoimidazole
Identifiers
CAS number	103577-45-3
ATC code	A02BC03
PubChem	3883
DrugBank	APRD00077
Chemical data
Formula	C16H14F3N3O2S
Mol. mass	369.363 g/mol
Pharmacokinetic data
Bioavailability	80% or more
Metabolism	Hepatic (CYP3A4- and CYP2C19-mediated)
Half life	1 - 1.5 hours
Excretion	Renal and fecal
Therapeutic considerations
Licence data	US
Pregnancy cat.	B3(AU) B(US)
Legal status	℞ Prescription only
Routes	Oral, IV

Lansoprazole (lan-SOE-pra-zole, INN) is a proton pump inhibitor which prevents the stomach from producing acid. It is manufactured by TAP Pharmaceutical Products.

Contents 1 Pharmacology 2 Indications 3 Contraindications 4 Side effects 5 Brand names 6 External links

[edit] Pharmacology

Lansoprazole is a proton pump inhibitor (PPI) in the same pharmacologic class as omeprazole. While lansoprazole has been marketed for many years, evidence has shown that it is one of the least potent PPI's in the market^{[citation needed]}. It is expected to receive OTC approval (like Prilosec OTC) after its patent expires in 2008^{[citation needed]}. Additionally - TAP Pharmaceuticals has reported their intent to file a s-isomer formulation of S-lansoprazole in a 60 mg dosage in 2008 after its parent compounds patent has expired in the United States.^{[citation needed]}

Lansoprazole's plasma elimination half-life is not proportional to the duration of the drug's effects (i.e. gastric acid suppression). The plasma elimination half-life is 1.5 hours or less^{[citation needed]}, and the effects of the drug last for over 24 hours after it has been used for 5 days or more.^{[citation needed]}

[edit] Indications

Lansoprazole is indicated for:

• Treatment of ulcers of the stomach and duodenum, and NSAID-induced ulcers
• Treatment of gastroesophageal reflux disease (GERD) (also known as acid reflux disease)
• Treatment of Zollinger-Ellison Syndrome
• Treatment of Barrett's esophagus
• Adjunctive treatment of Helicobacter pylori infection, alongside antibiotics

[edit] Contraindications

• Absorption of lansoprazole is reduced by antacids.
• PPI’s reduce absorption of antifungals (itraconazole and ketoconazole) and possibly increase Digoxin in plasma
• Increases plasma concentrations of Cilostazol (risk of toxicity)
• Absorption of lansoprazole possibly reduced by:
  • sucralfate
  • ampicillin
  • bisacodyl
  • delavirdine
  • fluvoxamine
  • iron salts
  • theophylline
  • voriconazole
  • aminophylline and theophylline
  • astemizole

[edit] Side effects

• Infrequent: dry mouth, insomnia, drowsiness, blurred vision, rash, pruritus
• Rarely and very rarely: taste disturbance, liver dysfunction, peripheral oedema, hypersensitivity reactions (including bronchospasm, urinary, angioedema, anaphylaxis), photosensitivity, fever, sweating, depression, interstitial nephritis, blood disorders (including leukopenia, leukocytosis, pancytopenia, thrombocytopenia), arthralgia, myalgia, skin reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous eruption)
• Increases the risk of gastric-intestinal infections by reducing gastric acidity.
• Severe: Gastro-intestinal disturbances (such as nausea, vomiting, abdominal pain, flatulence, diarrhea, constipation), headache, dizziness

[edit] Brand names

The drug is sold with the following brand names:

• Lansox® (Italy)
• Limpidex® (Italy)
• Prevacid® (U.S. and Canada)
• Takepron® (Japan)
• Zoton® (Italy)
• Refluxon® (Hungary)
• Lanzap®

Lansoprazole is also available as a generic drug in Italy and Mexico.

[edit] External links

• Prevacid (manufacturer's website)
• Prevacid Pediatrics (manufacturer's website)
• Prevpac® (manufacturer's website)
• Lansoprazole (patient information)